General Comments / Chat, page-9791

Yes - a combination of the ASX anti-ramping rules and the completely bizarre way ASH publishes abstracts. We all know about the ASX policy which makes it hard to announce preclinical results, but the ASH aspect is new. Unlike every other conference I have ever attended (over 50 in my life) what ASH does is truely strange. They publish your abstract unreviewed in the journal Blood and only later peer-review it for a poster or talk at the ASH conference. With this abstract ASH decided to not accept it for a presentation at the conference, but the abstract was still published. This blocks us from releasing a seperate ASX announcement.

I am writing a final end of year update for shareholders and will include this work in the announcement. It is highly relevant to the investigator initiated AML trial as it is the same drug combination that will be used in that trial - as you can see from the abstract this combination works really, really well in AML (in mice at least).